KKR agreed to acquire Integer Holdings in an all-cash transaction valued at $5.7 billion, removing the medical device contract manufacturer from public markets in one of the year's larger healthcare take-privates. The deal, expected to close by year-end, marks KKR's return to large-scale medtech infrastructure after a three-year focus on software-enabled healthcare services.
Integer manufactures components and finished devices for cardiac rhythm management, neuromodulation, and vascular systems—unsexy but high-margin work that sits between OEMs like Medtronic and Abbott and the patient. The company operates 30 facilities across 11 countries and reported $1.48 billion in trailing twelve-month revenue with EBITDA margins in the low-twenties. KKR is paying a premium to the 30-day volume-weighted average, though the exact multiple remains undisclosed. Integer's shares traded at $78 before acquisition chatter; the offer lands near $95.
The thesis is operational leverage and margin expansion under private ownership. Integer has been integrating two acquisitions—Lake Region Medical and Nuvectra—since 2021, a process that compressed margins and created integration debt. Public market patience for multi-year consolidation plays has thinned; private equity can afford the 18-24 month window to harmonize supply chains, rationalize SKUs, and cross-sell into existing customer bases. KKR's healthcare verticals team has done this twice before with Envision and Heartland Dental, though results varied.
The timing reflects a broader private equity pivot into healthcare infrastructure. Medtech CDMOs are attractive because they're non-discretionary vendors to large-cap OEMs locked into multi-year supply agreements. Integer's top 10 customers represent 65% of revenue, but contracts average 4.3 years with automatic renewals. This is annuity-like cash flow in a sector where FDA barriers and customer switching costs are structural moats. KKR can lever the business at 5-6x EBITDA, optimize working capital, and either dividend recap in year three or sell to a strategic in 5-7 years when the next wave of OEM consolidation hits.
Allocators should watch the debt structure KKR files in the next 30 days. If the deal is financed with 60%+ leverage, that signals confidence in Integer's contract stability but also leaves less room for margin disappointment. Follow-on moves to track: any facility closures in Q1 2027, which would indicate aggressive cost-cutting, and whether KKR brings in a new CFO or COO from their portfolio stable. The healthcare infrastructure desk at KKR has $14 billion in dry powder; if Integer performs, expect two more CDMO take-privates by mid-2027.
Integer's CEO stays on post-close. That's the detail that matters. KKR doesn't retain management unless the operational roadmap is already scoped and the executive can execute it without a babysitter.